Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
[13] [14] Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not receive GLP-1 medications due to the theoretical risk of thyroid C-cell tumors
However, it was still unclear whether the hormone would provide a clinical benefit in diabetic patients
In conclusion, the post-hoc data from the STEP UP trial suggest that the benefits of high-dose semaglutide are multi-faceted, offering promising results for renal preservation and the reduction of chronic inflammation in adults living with obesity
Lancet 2009;374:1606-1616 Erratum in: Lancet 2010;375:984
)
Clinical trials showed 15 to 24% body weight loss over one year
For both of these final limitations, the use of rich multimodal clinical data such as clinical notes to assess patient-level features driving motivation for GLP-1 use and discontinuation, as well as imaging to quantify and assess fat loss through CT scans could help shed light on the true impact of GLP-1s on body composition as well as patient profiles that are related to varying levels of treatment effect
